SRNE Stock Recent News
SRNE LATEST HEADLINES
When it comes to certain stocks to sell, being overly optimistic can become a liability. No, this is not a popular topic by any means, usually arousing anger among the investing faithful.
The drugmaker's stock is moving upward today in sympathy with the broader biopharmaceutical industry.
Sorrento's financials are not helping it in the current down market.
SAN DIEGO, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that Henry Ji, Ph.D., Chairman, President and Chief Executive Officer, and members of Sorrento's executive team will participate the 20th Annual Morgan Stanley Global Healthcare Conference:
Sorrento Therapeutics' (SRNE) subsidiary Scilex receives Fast Track designation for its lower back pain (LBP) candidate, SP-103. Stock Up.
An FDA fast track designation for a high-value product candidate is powering the biotech's shares higher today.
Source: Bukhta Yurii / Shutterstock.com Sorrento Therapeutics (NASDAQ: SRNE ) stock is getting a boost on Wednesday after the FDA granted it fast-track designation for SP-103. SP-103 is Sorrento Therapeutics' “non-opioid triple-strength, non-aqueous lidocaine topical system for the treatment of acute LBP.
Biopharmaceutical outfit Sorrento Therapeutics (US:SRNE) rallied +6.2% on Tuesday and extended gains by a further +2.1% in post market trading after the company released positive trial results cnx.cmd.push(function() {var videoId = decodeURIComponent(""); cnx({ playerId: "0a52d238-33b5-4c04-ba5e-323e192cfbe8", mediaId: videoId}).render("b8b49474e42e4a61905a1353db504ac9"); }); from Abivertinib that was used for the treatment of Advanced Non-Small Cell Lung Cancer (NSCLC).
Sorrento Therapeutics' (SRNE) stock rises after it announced positive results from its late-stage lung cancer study evaluating abivertinib.
These two penny stocks could generate life-changing gains for early shareholders.